The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Inactivation of p53 and Pten promotes invasive bladder cancer
Open accessAbstract
Although bladder cancer represents a serious health problem worldwide, relevant mouse models for investigating disease progression or therapeutic targets have been lacking. We show that combined deletion of p53 and Pten in bladder epithelium leads to invasive cancer in a novel mouse model. Inactivation of p53 and PTEN promotes tumorigenesis in human bladder cells and is correlated with poor survival in human tumors. Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies. Our integrated analyses of mouse and human bladder cancer provide a rationale for investigating mTOR inhibition for treatment of patients with invasive disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Self-citationCarracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
The coordinate regulation of the p53 and mTOR pathways in cells
Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A., & Cote, R. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311903 · Cited by 783
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
Hambardzumyan, D., Becher, O. J., Rosenblum, M. K., Pandolfi, P. P., Manova-Todorova, K., & Holland, E. C. (2008) · Genes & Development · doi:10.1101/gad.1627008 · Cited by 468
Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391
Self-citationDinney, C. P. N., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., Tuziak, T., Sabichi, A. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.002 · Cited by 290
Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas
Kwon, C.-H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D. K., Mason, R. P., Lee, E. Y.-H. P., Wu, H., & Parada, L. F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6867 · Cited by 270
Rigby, C. C., & Franks, L. M. (1970) · British Journal of Cancer · doi:10.1038/bjc.1970.89 · Cited by 255
Wang, M. Y., Lu, K. V., Zhu, S., Dia, E. Q., Vivanco, I., Shackleford, G. M., Cavenee, W. K., Mellinghoff, I. K., Cloughesy, T. F., Sawyers, C. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4392 · Cited by 240
Association of P53 Nuclear Overexpression and Tumor Progression in Carcinoma in situ of the Bladder
Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F., Sheinfeld, J., Fair, W. R., Herr, H. W., & Reuter, V. E. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)32745-3 · Cited by 211
Self-citationSänchez‐Carbayo, M., Socci, N. D., Charytonowicz, E., Lu, M.-L., Prystowsky, M. B., Childs, G. J., & Cordon‐Cardo, C. (2002) · PubMed · Cited by 197
Self-citationAltered Patterns of MDM2 and TP53 Expression in Human Bladder Cancer
Lianes, P., Orlow, I., Zhang, Z.-F., Oliva, M. R., Sarkis, A. S., Reuter, V. E., & Cordon-Cardo, C. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1325 · Cited by 194
Self-citationFan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192
Will mTOR inhibitors make it as cancer drugs?
Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00275-7 · Cited by 190
Zhang, Z. T., Pak, J., Shapiro, E., Sun, T., & Wu, X. (1999) · PubMed · Cited by 189
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers
Cairns, P., Evron, E., Okami, K., Halachmi, N., Esteller, M., Herman, J. G., Bose, S., Wang, S. I., Parsons, R., & Sidransky, D. (1998) · Oncogene · doi:10.1038/sj.onc.1201855 · Cited by 180
Somatic mutation of PTEN in bladder carcinoma
Aveyard, J. S., Skilleter, A., Habuchi, T., & Knowles, M. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690439 · Cited by 138
Molecular alterations associated with bladder cancer initiation and progression
Cordon‐Cardo, C. (2008) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/03008880802291915 · Cited by 126
Self-citationmTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
Tourneau, C. L., Faivre, S. J., Serova, M., & Raymond, É. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604636 · Cited by 115
Tsuruta, H., Kishimoto, H., Sasaki, T., Horie, Y., Natsui, M., Shibata, Y., Hamada, K., Yajima, N., Kawahara, K., Sasaki, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4627 · Cited by 109
Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo
Wendel, H., Malina, A., Zhao, Z., Zender, L., Kogan, S. C., Cordon‐Cardo, C., Pelletier, J., & Lowe, S. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0419 · Cited by 108
Self-citationLegrier, M., Yang, C. H., Yan, H.-G., Lopez-Barcons, L. A., Keller, S. M., Perez-Soler, R., Horwitz, S. B., & McDaid, H. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0702 · Cited by 94
Pten Deficiency Activates Distinct Downstream Signaling Pathways in a Tissue-Specific Manner
Yoo, L. I., Liu, D. W., Vu, S. L., Bronson, R. T., Wu, H., & Yuan, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1986 · Cited by 69
Genetic interactions between Pten and p53 in radiation-induced lymphoma development
Mao, J., Wu, D., Pérez‐Losada, J., Nagase, H., Delrosario, R., & Balmain, A. (2003) · Oncogene · doi:10.1038/sj.onc.1207083 · Cited by 46
Bladder cancer subtypes defined by genomic alterations
Knowles, M. A. (2008) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/03008880802284605 · Cited by 41
Wallerand, H., Reiter, R. E., & Ravaud, A. (2008) · Current Opinion in Urology · doi:10.1097/mou.0b013e3283097889 · Cited by 39
Novel agents for muscle‐invasive and advanced urothelial cancer
Sonpavde, G., Ross, R. W., Powles, T. B., Sweeney, C. J., Hahn, N. M., Hutson, T. E., Galsky, M. D., Lerner, S. P., & Sternberg, C. N. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07326.x · Cited by 14
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
A Molecular Taxonomy for Urothelial Carcinoma
Sjödahl, G., Lauss, M., Lövgren, K., Chebil, G., Gudjonsson, S., Veerla, S., Patschan, O., Aine, M., Fernö, M., Ringnér, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0077-t · Cited by 944
Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Metadata
- Authors
- Puzio-Kuter, A. M., Castillo-Martin, M., Kinkade, C. W., Wang, X., Shen, T. H., Matos, T., Shen, M. M., Cordon-Cardo, C., & Abate-Shen, C.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2009-03-04
- Volume
- 23
- Issue
- 6
- Pages
- 675-680
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2147711252
- Cited by
- 329
- References
- 36
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.